Russian universities near completing Angipur, a new antiplatelet substance compared with eptifibatide in 157 patients

Researchers from Volgograd and Bashkortostan are completing development of Angipur, which pravda.ru describes as the first original Russian drug for the treatment and prevention of myocardial infarction pravda.rupravda.rupravda.ruOpen source ↗. Unlike generics, it is based on a new molecule synthesized from scratch. The developers present it as an alternative to imported antithrombotic agents.

The project took 10 years. Chemists at Bashkir State Medical University synthesized the active substance, and specialists at Volgograd State Medical University carried out preclinical safety and efficacy studies in laboratory animals. The project is overseen by the company Elta.

Mechanism and intended use

The substance is aimed at preventing platelet aggregation and blocking thrombus formation. This is important in acute cardiovascular conditions and during coronary stent placement, which is performed to restore blood flow.

Patient testing and development status

Efficacy was tested in a group of 157 patients with high-risk acute coronary syndrome pravda.rupravda.rupravda.ruOpen source ↗. In comparison with eptifibatide, Angipur showed comparable or better results. According to the researchers, the original formula could potentially reduce the risk of bleeding, one of the main complications of antithrombotic therapy.

The substance is at the final stage of development. Viktor Sirotenko, Doctor of Pharmaceutical Sciences and dean of the pharmaceutical faculty at Volgograd State Medical University, said it could reach the market within two years. The claim of a better safety profile and the final clinical efficacy will be confirmed only after all registration stages are completed and the drug is introduced into medical practice.